Ye Li-Hua, Ma Xiao, Xu Shu-Cai
Department of Oncology and Hematology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan 430015, Hubei Province, China.
Department of Oncology and Hematology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan 430015, Hubei Province, China,E-mail：
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Apr;29(2):445-449. doi: 10.19746/j.cnki.issn.1009-2137.2021.02.022.
To investigate the expression of microRNA-370 (miR-370) and microRNA-203 (miR-203) in the serum of patients with acute myeloid leukemia(AML), and to analyze its clinical diagnosis and prognostic significance.
57 patients with acute myeloid leukemia were enrolled as experimental group, and 21 healthy people were enrolled as control group. The fasting venous blood of the personal in the two groups were collected. The expression of miR-370 and miR-203 of the personal in each groups were detected by real-time fluorescent quantitative PCR. The receiver operating characteristic (ROC) curve was plotted to detected the diagnostic values of serum miR-370, miR-203, and the Kaplan-Meier method was used to estimate the relationship between expression and overall survival of the patients.
Compared with healthy controls, serum miR-370 expression was significantly decreased in AML patients(P<0.05), and serum miR-203 expression was also significantly decreased (P<0.05). ROC curve analysis showed that the expression of serum miR-370 and miR-203 could be used to distinguish acute myeloid leukemia and healthy people. The area under the ROC curve of miR-370 was 0.909, and the sensitivity and specificity were 91.46% and 100.00%, respectively. The area under the ROC curve of miR-203 was 0.895, and the sensitivity and specificity were 83.45% and 89.71%, respectively. Serum levels of miR-370 and miR-203 were closely related to overall survival in AML patients.
The expression of miR-370 and miR-203 is decreased in the serum of patients with AML and may be a new markers for the diagnosis and prognosis of AML.
探讨急性髓系白血病（AML）患者血清中微小RNA-370（miR-370）和微小RNA-203（miR-203）的表达情况，并分析其临床诊断及预后意义。
选取57例急性髓系白血病患者作为实验组，21例健康人作为对照组。采集两组人员的空腹静脉血。采用实时荧光定量PCR检测各组人员血清中miR-370和miR-203的表达。绘制受试者工作特征（ROC）曲线以检测血清miR-370、miR-203的诊断价值，并采用Kaplan-Meier法评估其表达与患者总生存的关系。
与健康对照组相比，AML患者血清miR-370表达显著降低（P<0.05），血清miR-203表达也显著降低（P<0.05）。ROC曲线分析显示，血清miR-370和miR-203的表达可用于区分急性髓系白血病患者和健康人。miR-370的ROC曲线下面积为0.909，灵敏度和特异度分别为91.46%和100.00%。miR-203的ROC曲线下面积为0.895，灵敏度和特异度分别为83.45%和89.71%。血清miR-370和miR-203水平与AML患者的总生存密切相关。
AML患者血清中miR-370和miR-203表达降低，可能成为AML诊断及预后评估的新标志物。
